← All news
Markets
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
Covered by 1 outlet
All coverage · 1 article